CVRx stock gained 3.85 percent ahead of Barostim data
Published on 10/07/2026 at 05:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CVRx stock (ISIN US1266381052) gained 3.85 percent to close at USD 1.62 on Nasdaq on October 6, 2026. The next company checkpoint is Barostim's appearance at the Heart Failure Society of America meeting, where CVRx said on September 29, 2026, that the therapy would feature in eight events starting October 9.
Barostim data set the next test
The HFSA program includes late-breaking analyses from the REBALANCE Registry, real-world evidence on Barostim in a heart-failure population, and presentations tied to the BENEFIT-HF trial. CVRx will also host two symposia on integrating Barostim into heart-failure care, giving the event a broader commercial and clinical role than a single data presentation.
For investors, the key question is whether new evidence can improve confidence in adoption while the company addresses sales execution and reimbursement pressure. Investing.com reported on September 22, 2026, that the company had cited those operating issues while maintaining its 2026 outlook discussion.
Revenue grows while losses persist
CVRx reported USD 15.71 million of second-quarter 2026 revenue and diluted EPS of negative USD 0.53. MarketBeat said the revenue result exceeded the USD 15.55 million consensus, while EPS missed the USD 0.52 loss estimate by USD 0.01.
The comparison shows the investment case's split clearly: sales are expanding, but the latest quarter still produced a substantial per-share loss. CVRx's commercial-stage model centers on Barostim, an implantable neuromodulation system designed to improve symptoms for eligible heart-failure patients.
Consensus target remains above the stock
MarketBeat lists a Hold consensus based on six analysts, with two Buy ratings, three Hold ratings and one Sell rating. Its average price target is USD 4.30, with a USD 3.50 low and USD 5.00 high; the average target lies 165.4 percent above the October 6 closing price.
That spread reflects both the potential value assigned to Barostim and the execution risk embedded in a loss-making medical-device business. CVRx stock remains within a USD 1.50 to USD 11.30 52-week range, leaving the October 6 close 46.0 percent above the low and 85.7 percent below the high.
CVRx stock closes at USD 1.62
CVRx stock closed at USD 1.62 on Nasdaq at 4:00 p.m. ET on October 6, 2026, with volume of 537,123 shares and market capitalization of USD 43.2 million.
CVRx stock facts
- Company: CVRx, Inc.
- ISIN: US1266381052
- Ticker: CVRX
- Trading venue: NASDAQ
- Price (as of October 6, 2026, 4:00 p.m. ET): USD 1.62, Closing price (October 6, 2026)
- Market capitalization: USD 43.2 million (as of October 6, 2026)
- 52-week range: USD 1.50-11.30 (as of October 6, 2026)
- Sector / Industry: Healthcare / Healthcare Equipment and Supplies
Upcoming dates for CVRx stock
- October 9, 2026: HFSA Annual Scientific Meeting begins with Barostim presentations
